Churbz: The key to the ESS deal is Joseph Rubenfeld, who is associated with both Reginicen and Amarantus. The reason AMBS got ESS with so little cash is because Reginicen valued the shares of Amarantus they picked up. (MANF) However, if we sell the litigation free ESS now to someone else, they may be willing to pay for it's true value in straight cash. Maybe we pick up 15 million up and above the price we paid....in cash. This could be a unique way of leveraging the future value of MANF and getting much needed cash up front to fund Eltoprazine.

It's merely a theory. Somehow, we need cash to fund our pipeline. That is what is needed to get the stock price moving up again.